Jul 7, 2026 · 6 min
Samsung fallout rattles memory stocks as SpaceX joins Nasdaq 100
Micron and Sandisk Drop; SpaceX Rating; Crinetics Soars
The episode connects one semiconductor giant’s earnings with investor reactions across memory chips, aerospace, payments, and pharmaceuticals.
- 1Samsung’s earnings fallout weighs on memory-chip companies Micron Technology and SanDisk.
- 2SpaceX’s Nasdaq 100 entry arrives alongside positive broker ratings and renewed market attention.
- 3Vertex Pharmaceuticals’ proposed $10 billion acquisition of Crinetics reshapes the pharmaceutical story discussed here.
Don't miss
The episode’s clearest corporate-action moment is Vertex Pharmaceuticals’ proposed $10 billion acquisition of Crinetics Pharmaceuticals.
The brief
Samsung’s earnings set the tone for a sharp move in global memory stocks, with Micron Technology and SanDisk absorbing the fallout.
SpaceX brings a different kind of market catalyst: entry into the Nasdaq 100, reinforced by positive broker ratings and heightened investor attention.
The discussion then turns to payments, where a potential bank acquisition involving a Fiserv-owned network adds a strategic angle to the day’s movers.
The biggest deal story is Vertex Pharmaceuticals’ proposed $10 billion acquisition of Crinetics Pharmaceuticals, extending the roundup beyond technology.
Together, the moves show how earnings, index membership, ratings, corporate strategy, and acquisitions can drive sharply different stock narratives in one session.
What was said on this episode
10 statements · 5 positive · 3 negative · 2 neutral
Micron and SanDisk shares fell 5% in premarket trading.
“Micron Ticker mu is down 5%. SanDisk S&DK also down the same amount.”
Listen at 1:08
Samsung’s 6% earnings beat was insufficient to support memory stocks.
“there's a lot of expectation in this very high flying sector and a 6% beat, not just quite enough to support the memory space.”
Listen at 1:34
Strategists say memory-sector underperformance is somewhat excessive.
“strategists saying that the, that the underperformance from the sector is a little bit overdone compared to say the inputs.”
Listen at 1:55
Morgan Stanley set SpaceX’s price target at $300, nearly twice its current price.
“Morgan Stanley among one of those brokerages. It has a $300 price target. That's nearly two times where it is trading now.”
Listen at 2:40
Goldman Sachs set a $205 price target for SpaceX.
“Goldman Sachs has a little bit more Moderate price target. 205.”
Listen at 2:50
Analysts’ average SpaceX price target of $216 implies meaningful upside.
“Overall we have 23 Buys, 4 Holds and 1 Sell. Average price target of 216. So still implying a decent upside from”
Listen at 2:53
JPMorgan and Bank of America are exploring acquiring Fiserv’s payment network.
“Some of the biggest banks, including JP Morgan and Bank of America have been exploring an acquisition of the payment network owned by fiserv.”
Listen at 3:09
Vertex agreed to acquire Crinetics for $10 billion in cash.
“Vertex has agreed to buy Crenex for $10 billion in cash.”
Listen at 3:54
The Crinetics acquisition will give Vertex entry into endocrinology.
“This will give Vertex an entry into the endocrinology market.”
Listen at 4:09
The Crinetics acquisition will diversify Vertex beyond its single-treatment revenue concentration.
“Vertex currently gets 85% of its revenue from a single treatment. So this will help expand out its market and its offerings.”
Listen at 4:12
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
SanDisk
Vertex PharmaceuticalsListen to the full episode and explore every guest, topic, and moment on PodLume.